当前位置： SCI文献检索 > BRITISH JOURNAL OF CANCER期刊下所有文献 > Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas.

Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas.

Abstract：

BACKGROUND:Heterogeneity and low incidence comprise the biggest challenge in sarcoma diagnosis and treatment. Chemotherapy, although efficient for some sarcoma subtypes, generally results in poor clinical responses and is mostly recommended for advanced disease. Specific genomic aberrations have been identified in some sarcoma subtypes but few of them can be targeted with approved drugs. METHODS:We cultured and characterised patient-derived sarcoma cells and evaluated their sensitivity to 525 anti-cancer agents including both approved and non-approved drugs. In total, 14 sarcomas and 5 healthy mesenchymal primary cell cultures were studied. The sarcoma biopsies and derived cells were characterised by gene panel sequencing, cancer driver gene expression and by detecting specific fusion oncoproteins in situ in sarcomas with translocations. RESULTS:Soft tissue sarcoma cultures were established from patient biopsies with a success rate of 58%. The genomic profile and drug sensitivity testing on these samples helped to identify targeted inhibitors active on sarcomas. The cSrc inhibitor Dasatinib was identified as an active drug in sarcomas carrying chromosomal translocations. The drug sensitivity of the patient sarcoma cells ex vivo correlated with the response to the former treatment of the patient. CONCLUSIONS:Our results show that patient-derived sarcoma cells cultured in vitro are relevant and practical models for genotypic and phenotypic screens aiming to identify efficient drugs to treat sarcoma patients with poor treatment options.

journal_name

Br J Cancer

journal_title

British journal of cancer

authors

Brodin BA,Wennerberg K,Lidbrink E,Brosjö O,Potdar S,Wilson JN,Ma L,Moens LN,Hesla A,Porovic E,Bernhardsson E,Papakonstantinou A,Bauer H,Tsagkozis P,von Sivers K,Wejde J,Östling P,Kallioniemi O,Stragliotto CL

doi

10.1038/s41416-018-0359-4

subject

Has Abstract

pub_date

2019-02-01 00:00:00

pages

435-443

issue

eissn

0007-0920

issn

1532-1827

pii

10.1038/s41416-018-0359-4

journal_volume

120

pub_type

杂志文章

在线工具

Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas.